Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate

Nathan, Anthony W.; Hellestrand, Kevin J.; Bexton, R. S.; Banim, S. O.; Spurrell, R. A. J.; Camm, A. John

doi:10.1016/0002-8703(84)90368-5

Cited by 76 publications

(16 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prolongation of the PR interval and widening of the QRS complex are characteristic features of the action of class IC AADs such as flecainide and propafenone [35,36]. Flecainide has been reported to be associated with widening of the QRS complex in 15-30% of patients, as well as with transient arrhythmias and left ventricular decompensation [37].…”

Section: Other Proarrhythmiasmentioning

confidence: 99%

Safety considerations in the pharmacological management of atrial fibrillation

Camm¹

2008

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Other Proarrhythmiasmentioning

confidence: 99%

Safety considerations in the pharmacological management of atrial fibrillation

Camm¹

2008

International Journal of Cardiology

View full text Add to dashboard Cite

“…The PR, QRS, AH, HV, and QT intervals are all prolonged [49]. In addition, flecainide generally prolongs refractoriness of accessory pathways [50]. The half-life is long (mean, 14 hours), and the drug may be administered twice daily.…”

Section: Vaughn Williams Classification Of Antiarrhythmic Agentsmentioning

confidence: 99%

“…Flecainide suppresses ventricular premature beats and nonsustained ventricular tachycardia very effectively [51] and is useful in treating WolffParkinson-White syndrome with either atrioventricular reentrance or rapid ventricular response to atrial fibrillation [50]. Results of testing of flecainide by programmed stimulation in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation have been variable, with reported efficacies from 15 to 65% [52].…”

Section: Vaughn Williams Classification Of Antiarrhythmic Agentsmentioning

confidence: 99%

Advances in the Management of Tachyarrhythmias

Herre

1987

J Intensive Care Med

View full text Add to dashboard Cite

Recent developments of both diagnostic and therapeu tic techniques in the management of tachyarrhythmias have broadened the options available to physicians car ing for patients with tachyarrhythmias. Newer diag nostic methods allow more precise identification of the arrhythmia and better understanding of its mechanism. Long-term epidemiologic studies have identified groups of patients who do and do not require antiarrhythmic therapy. Antitachycardia pacemakers and automatic im plantable defibrillators allow effective treatment for pa tients for whom drugs were ineffective or in whom in tolerable side effects developed. Finally, several new antiarrhythmic agents have become available recently. Proper use of these new techniques and drugs requires greater understanding of the pathophysiology of cardiac arrhythmias.

show abstract

“…Symptoms such as taste disturbances, anesthesia or dysesthesia of the tongue or throat, and paresthesias of the fingers can be explained by the local anesthetic effect of the drug. The dosedependent side effects decrease or disappear in the majority of patients within a few days; in about 6-10% they lead to discontinuation of treatment (Gentzkow and Sullivan, 1984;Nathan et al, 1984a Sigwart and MoCostabella, 1982).…”

Section: Side Effects Precautionary Measuresmentioning

confidence: 99%

Flecainide: A new antiarrhythmic drug

Mueller

Baur

1986

Clinical Cardiology

View full text Add to dashboard Cite

Summary: Flecainide acetate is a new class lc antiarrhythmic drug. It slows conduction in the working myocardium and the specialized conduction system and may depress sinus node activity in patients with pre-existing sinus node disease. Its hernodynamic effects are minimal. The drug is completely absorbed and shows a half-life of 7-22 hours. Elimination is mainly through the kidneys. Flecainide is highly effective in the treatment of ventricular arrhythmias, pre-excitation syndromes and AV reentry tachycardias. Side effects axe mild and consist mostly of dizziness, visual disturbances, and nervousness. They rarely require discontinuation of therapy. Proarrhythmic effects have been reported. Caution is required in patients with congestive heart failure, AV block, and/or bundlebranch block or sinus node dysfunction.

show abstract

Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate

Cited by 76 publications

References 36 publications

Safety considerations in the pharmacological management of atrial fibrillation

Safety considerations in the pharmacological management of atrial fibrillation

Advances in the Management of Tachyarrhythmias

Flecainide: A new antiarrhythmic drug

Contact Info

Product

Resources

About